DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...
Five-stop trade show roadmap across Germany, Spain and Poland to showcase transducerized tightening, servo pressing, automated screw feeding and precision dispensing solutionsMUNICH, June 4,...
Maranello (Italy), June 3, 2026 - Ferrari N.V. (NYSE/EXM: RACE) announces the multi-year renewal of the agreement between Scuderia Ferrari HP and Charles Leclerc.
Eletre X is built for drivers who refuse to compromise - delivering ultimate performance, 1,200+ km of range, and 9-minute charging in a practical hybrid SUV.1 Available to order today, starting from €96,990.
ROCHESTER, N.Y., June 02, 2026 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its first quarter ended May 31, 2026, on Tuesday, June 30, 2026, after the close of the U.S. markets by posting the earnings release and financial tables, as well as other supporting materials, on the company’s investor relations website at ir.cbrands.com. A live conference call will be hosted at 8:00 a.m. ET on Wednesday, July 1, 2026, for analysts to discuss the company’s financial results, operating performance, strategic business initiatives, and financial outlook with President and Chief Executive Officer, Nicholas Fink, and Executive Vice President and Chief Financial Officer, Garth Hankinson.
Phoenix, AZ, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SETT, a men’s jewelry brand known merging aesthetic simplicity with personalization, has announced the upcoming launch of its newest collection: SETT NOIR – sterling silver men’s bracelet fusing three distinct finishes: black rhodium, white rhodium, and gold plating. Defined by its rich contrast and meticulous design, the collection marks a bold shift toward more sophisticated, contemporary luxury design within the brand’s portfolio.
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...